Lucentis for Central Retinal Vein Occlusion (CRVO)

Conditions

• Central Retinal Vein Occlusion

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ranibizumab — DRUG
  0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally

Study Details

The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).

Key Dates

First listed

Dec 4, 2006

Start date

Jan 31, 2006

Status verified

Dec 2013

Primary completion

Sep 30, 2008

Completion

Oct 31, 2010

Study Design

Enrollment

20 participants (actual)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Active Comparator: 1
  0.5mg Ranibizumab
• Active Comparator: 2
  0.3mg Ranibizumab

Primary Outcome Measure

The primary objective is to determine the proportion of subjects in each group ( 0.3, 0.5 mg ) gaining 15 or more letters at month 6 and 12 (ETDRS visual refraction at 4 meters) and to determine if a difference exists between the high and low dose. [ Time Frame: 6 and 12 months ]

Locations (4)

Find similar trials in Bakersfield, CA